We are analyzing https://link.springer.com/article/10.1007/bf01806494.

Title:
Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma | Breast Cancer Research and Treatment
Description:
In a series of 205 node-negative breast cancers (NNBC), we determined staining by the novel antibody Ki-S1, a marker of tumor cell proliferation, in order to test its association with other prognostic variables and its prognostic significance. Ki-S1 was determined in routinely formalin-fixed paraffin-embedded tumor samples. Ki-S1 gave a nuclear staining in the majority of the carcinomas (188 of 205), with percentages of reacting nuclei ranging from 2% to 90% (median value of 7%). In 107 tumors frozen sections were available to also assess the Ki-67 antibody. Among these, 94 had a nuclear staining of cancer cells ranging from 5% to 80% (median value of 7%). In 46 tumors we also determined the MIB-1 antibody. The percentage of MIB-1 nuclear staining ranged from 1% to 50% (median value of 20%). There was no significant relationship between Ki-S1 and the other two cell kinetic markers. Ki-S1 labeling was significantly associated only with tumor size (p = 0.03). With a median follow-up of 6 years, Ki-S1 had no significant prognostic value for either relapse-free survival (RFS) or overall survival (OS)(Ki-S1 as continuous logarithmic variable; p = 0.86 and p = 0.23, respectively). For RFS the following variables had a significant prognostic value: Ki-67 (≤ 10% vs > 10%; p = 0.037); progesterone receptor (PgR) expression (− vs +/++; p = 0.041); tumor size (pT1 vs pT2−3; p = 0.042) and grading (GI vs GII−III; p = 0.047). For OS, tumor size (p = 0.0044), age (continuous variable; p = 0.0060), and Ki-67 (p = 0.043) were significantly prognostic. In multivariate analysis (final model), only tumor size retained a significant and independent prognostic value for RFS (p = 0.0042). For OS, both tumor size (p = 0.0029) and age (≤ 55 years vs > 55 years; p = 0.041) retained significance in the multivariate model. In conclusion, Ki-S1 does not seem to have prognostic relevance in this series of NNBC. Possible hypotheses to explain this observation are discussed.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

google, scholar, cancer, breast, pubmed, prognostic, antibody, kis, cell, article, monoclonal, gasparini, proliferation, nuclear, significance, carcinoma, bevilacqua, tumor, pathol, nodenegative, mib, prognosis, clin, privacy, cookies, research, marker, proliferative, boracchi, staining, markers, size, survival, human, antigen, content, analysis, data, log, publish, search, paolo, verderio, barbareschi, determined, median, cells, significant, access, fraction,

Topics {✒️}

node-negative breast cancer node-negative breast carcinoma c-erbb-2 oncoprotein compared month download article/chapter long-term prognosis significance mouse-monoclonal antibody reactive paraffin-embedded tissues cytofluorimetric s-phase fraction early-stage breast carcinoma monoclonal antibody ki-s1 human breast cancer cell kinetic markers dalla palma privacy choices/manage cookies invasive breast cancer operable breast cancer s-phase fraction human nuclear antigen tumor cell proliferation monoclonal kd-68 antibody antibody ki-s1 cancer cells ranging breast cancer survival chiara medical centre full article pdf ki-s1 gave ki-s1 labeling recognizes proliferating cells detect proliferating cells proliferating nuclear antigen nuclear antigen detectable monoclonal-antibody analysis european economic area reacting nuclei ranging thymidine labeling index flow cytometric assessment comparing radical mastectomy rapidly degraded proteins conditions privacy policy dna flow cytometry bacterially expressed parts conventional pathologic features paolo verderio accepting optional cookies cell proliferative rate mattia barbareschi continuous logarithmic variable check access instant access tumor size retained

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma
         description:In a series of 205 node-negative breast cancers (NNBC), we determined staining by the novel antibody Ki-S1, a marker of tumor cell proliferation, in order to test its association with other prognostic variables and its prognostic significance. Ki-S1 was determined in routinely formalin-fixed paraffin-embedded tumor samples. Ki-S1 gave a nuclear staining in the majority of the carcinomas (188 of 205), with percentages of reacting nuclei ranging from 2% to 90% (median value of 7%). In 107 tumors frozen sections were available to also assess the Ki-67 antibody. Among these, 94 had a nuclear staining of cancer cells ranging from 5% to 80% (median value of 7%). In 46 tumors we also determined the MIB-1 antibody. The percentage of MIB-1 nuclear staining ranged from 1% to 50% (median value of 20%). There was no significant relationship between Ki-S1 and the other two cell kinetic markers. Ki-S1 labeling was significantly associated only with tumor size (p = 0.03). With a median follow-up of 6 years, Ki-S1 had no significant prognostic value for either relapse-free survival (RFS) or overall survival (OS)(Ki-S1 as continuous logarithmic variable; p = 0.86 and p = 0.23, respectively). For RFS the following variables had a significant prognostic value: Ki-67 (≤ 10% vs > 10%; p = 0.037); progesterone receptor (PgR) expression (− vs +/++; p = 0.041); tumor size (pT1 vs pT2−3; p = 0.042) and grading (GI vs GII−III; p = 0.047). For OS, tumor size (p = 0.0044), age (continuous variable; p = 0.0060), and Ki-67 (p = 0.043) were significantly prognostic. In multivariate analysis (final model), only tumor size retained a significant and independent prognostic value for RFS (p = 0.0042). For OS, both tumor size (p = 0.0029) and age (≤ 55 years vs > 55 years; p = 0.041) retained significance in the multivariate model. In conclusion, Ki-S1 does not seem to have prognostic relevance in this series of NNBC. Possible hypotheses to explain this observation are discussed.
         datePublished:
         dateModified:
         pageStart:123
         pageEnd:133
         sameAs:https://doi.org/10.1007/BF01806494
         keywords:
            breast cancer
            immunocytochemistry
            Ki-S1 antibody
            prognosis
            proliferation markers
            Oncology
         image:
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:37
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Pierantonio Bevilacqua
               affiliation:
                     name:St. Bartolo Regional Medical Centre
                     address:
                        name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Paolo Verderio
               affiliation:
                     name:University of Milan
                     address:
                        name:Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mattia Barbareschi
               affiliation:
                     name:St. Chiara Medical Centre
                     address:
                        name:St. Chiara Medical Centre, Trento, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Emanuela Bonoldi
               affiliation:
                     name:St. Bartolo Regional Medical Centre
                     address:
                        name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Patrizia Boracchi
               affiliation:
                     name:University of Milan
                     address:
                        name:Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Paolo Dalla Palma
               affiliation:
                     name:St. Chiara Medical Centre
                     address:
                        name:St. Chiara Medical Centre, Trento, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Giampietro Gasparini
               affiliation:
                     name:St. Bartolo Regional Medical Centre
                     address:
                        name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma
      description:In a series of 205 node-negative breast cancers (NNBC), we determined staining by the novel antibody Ki-S1, a marker of tumor cell proliferation, in order to test its association with other prognostic variables and its prognostic significance. Ki-S1 was determined in routinely formalin-fixed paraffin-embedded tumor samples. Ki-S1 gave a nuclear staining in the majority of the carcinomas (188 of 205), with percentages of reacting nuclei ranging from 2% to 90% (median value of 7%). In 107 tumors frozen sections were available to also assess the Ki-67 antibody. Among these, 94 had a nuclear staining of cancer cells ranging from 5% to 80% (median value of 7%). In 46 tumors we also determined the MIB-1 antibody. The percentage of MIB-1 nuclear staining ranged from 1% to 50% (median value of 20%). There was no significant relationship between Ki-S1 and the other two cell kinetic markers. Ki-S1 labeling was significantly associated only with tumor size (p = 0.03). With a median follow-up of 6 years, Ki-S1 had no significant prognostic value for either relapse-free survival (RFS) or overall survival (OS)(Ki-S1 as continuous logarithmic variable; p = 0.86 and p = 0.23, respectively). For RFS the following variables had a significant prognostic value: Ki-67 (≤ 10% vs > 10%; p = 0.037); progesterone receptor (PgR) expression (− vs +/++; p = 0.041); tumor size (pT1 vs pT2−3; p = 0.042) and grading (GI vs GII−III; p = 0.047). For OS, tumor size (p = 0.0044), age (continuous variable; p = 0.0060), and Ki-67 (p = 0.043) were significantly prognostic. In multivariate analysis (final model), only tumor size retained a significant and independent prognostic value for RFS (p = 0.0042). For OS, both tumor size (p = 0.0029) and age (≤ 55 years vs > 55 years; p = 0.041) retained significance in the multivariate model. In conclusion, Ki-S1 does not seem to have prognostic relevance in this series of NNBC. Possible hypotheses to explain this observation are discussed.
      datePublished:
      dateModified:
      pageStart:123
      pageEnd:133
      sameAs:https://doi.org/10.1007/BF01806494
      keywords:
         breast cancer
         immunocytochemistry
         Ki-S1 antibody
         prognosis
         proliferation markers
         Oncology
      image:
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:37
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Pierantonio Bevilacqua
            affiliation:
                  name:St. Bartolo Regional Medical Centre
                  address:
                     name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Paolo Verderio
            affiliation:
                  name:University of Milan
                  address:
                     name:Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mattia Barbareschi
            affiliation:
                  name:St. Chiara Medical Centre
                  address:
                     name:St. Chiara Medical Centre, Trento, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Emanuela Bonoldi
            affiliation:
                  name:St. Bartolo Regional Medical Centre
                  address:
                     name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Patrizia Boracchi
            affiliation:
                  name:University of Milan
                  address:
                     name:Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Paolo Dalla Palma
            affiliation:
                  name:St. Chiara Medical Centre
                  address:
                     name:St. Chiara Medical Centre, Trento, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Giampietro Gasparini
            affiliation:
                  name:St. Bartolo Regional Medical Centre
                  address:
                     name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:37
Organization:
      name:Kluwer Academic Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:St. Bartolo Regional Medical Centre
      address:
         name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
         type:PostalAddress
      name:University of Milan
      address:
         name:Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy
         type:PostalAddress
      name:St. Chiara Medical Centre
      address:
         name:St. Chiara Medical Centre, Trento, Italy
         type:PostalAddress
      name:St. Bartolo Regional Medical Centre
      address:
         name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
         type:PostalAddress
      name:University of Milan
      address:
         name:Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy
         type:PostalAddress
      name:St. Chiara Medical Centre
      address:
         name:St. Chiara Medical Centre, Trento, Italy
         type:PostalAddress
      name:St. Bartolo Regional Medical Centre
      address:
         name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Pierantonio Bevilacqua
      affiliation:
            name:St. Bartolo Regional Medical Centre
            address:
               name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
               type:PostalAddress
            type:Organization
      name:Paolo Verderio
      affiliation:
            name:University of Milan
            address:
               name:Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy
               type:PostalAddress
            type:Organization
      name:Mattia Barbareschi
      affiliation:
            name:St. Chiara Medical Centre
            address:
               name:St. Chiara Medical Centre, Trento, Italy
               type:PostalAddress
            type:Organization
      name:Emanuela Bonoldi
      affiliation:
            name:St. Bartolo Regional Medical Centre
            address:
               name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
               type:PostalAddress
            type:Organization
      name:Patrizia Boracchi
      affiliation:
            name:University of Milan
            address:
               name:Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy
               type:PostalAddress
            type:Organization
      name:Paolo Dalla Palma
      affiliation:
            name:St. Chiara Medical Centre
            address:
               name:St. Chiara Medical Centre, Trento, Italy
               type:PostalAddress
            type:Organization
      name:Giampietro Gasparini
      affiliation:
            name:St. Bartolo Regional Medical Centre
            address:
               name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
      name:Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy
      name:St. Chiara Medical Centre, Trento, Italy
      name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
      name:Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy
      name:St. Chiara Medical Centre, Trento, Italy
      name:Department of Oncology, St. Bartolo Regional Medical Centre, Vicenzo, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(96)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.15s.

LINK . SPRINGER . COM {}